A novel reporter system for neutralizing and enhancing antibody assay against dengue virus

BMC Microbiology

Volumn 14, Issue 1, 2014, Pages

  Song, Ke Yu ^a,b   Zhao, Hui ^a   Jiang, Zhen You ^b   Li, Xiao Feng ^a   Deng, Yong Qiang ^a   Jiang, Tao ^a   Zhu, Shun Ya ^a   Shi, Pei Yong ^c   Zhang, Bo ^d   Zhang, Fu Chun ^e   Qin, E De ^a   Qin, Cheng Feng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^c NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^d WUHAN INSTITUTE OF VIROLOGY   (China)

^e Guangzhou Eighth People's Hospital   (China)

Author keywords

Dengue virus; Enhancing antibody; Luciferase assay; Neutralizing antibody

Indexed keywords

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; DENGUE VIRUS; GENES, REPORTER; HUMANS; IMMUNOASSAY; LUCIFERASES, RENILLA; REPRODUCIBILITY OF RESULTS; VIROLOGY;

EID: 84894522740     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-14-44     Document Type: Article

References (36)

1. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Gubler DJ, Trends Microbiol 2002 10 100 103 10.1016/S0966-842X(01)02288-0 11827812 (Pubitemid 34119347)
2. Dengue. Simmons CP, Farrar JJ, Nguyen vV, Wills B, N Engl J Med 2012 366 1423 1432 10.1056/NEJMra1110265 22494122
3. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Adams B, Holmes EC, Zhang C, Mammen MP Jr, Nimmannitya S, Kalayanarooj S, Boots M, Proc Natl Acad Sci U S A 2006 103 14234 14239 10.1073/pnas.0602768103 16966609 (Pubitemid 44453009)
4. Dengue. Halstead SB, Lancet 2007 370 1644 1652 10.1016/S0140-6736(07) 61687-0 17993365 (Pubitemid 350052290)
5. Neutralization and antibody-dependent enhancement of dengue viruses. Halstead SB, Adv Virus Res 2013 60 421 467
6. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. Halstead SB, O'Rourke EJ, J Exp Med 1977 146 201 217 10.1084/jem.146.1.201 406347 (Pubitemid 8139503)
7. Dengue virus identification by the plaque reduction neutralization test. Russell PK, Nisalak A, J Immunol 1967 99 291 296 4961907
8. Dengue vaccine development and dengue viral neutralization and enhancement assays. Jin X, Block OT, Rse R, Schlesinger J, Antivir Ther 2009 14 739 749 10.3851/IMP1288 19812436
9. Development and characterization of a stable luciferase dengue virus for high-throughput screening. Zou G, Xu HY, Qing M, Wang QY, Shi PY, Antiviral Res 2011 91 11 19 10.1016/j.antiviral.2011.05.001 21575658
10. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Henchal EA, Gentry MK, McCown JM, Brandt WE, Am J Trop Med Hyg 1982 31 830 836 6285749 (Pubitemid 12041595)
11. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, Yang HO, Tan WL, Liu R, Yu M, Ge BX, Zhu QY, Qin ED, Guo YJ, Qin CF, PLoS One 2011 6 16059 10.1371/journal.pone.0016059 21264311
12. Rapid detection of anti-Vaccinia virus neutralizing antibodies. Kramski M, Drozd A, Lichtfuss GF, Dabrowski PW, Ellerbrok H, Virol J 2011 8 139 10.1186/1743-422X-8-139 21439060
13. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. Kraus AA, Messer W, Haymore LB, de Silva AM, J Clin Microbiol 2007 45 3777 3780 10.1128/JCM.00827-07 17804661 (Pubitemid 350156883)
14. Studies of neutralising antibodies to SV40 in human sera. Minor P, Pipkin P, Jarzebek Z, Knowles W, J Med Viol 2003 70 490 495 (Pubitemid 36638066)
15. An infectious West Nile virus that expresses a GFP reporter gene. Pierson TC, Diamond MS, Ahmed AA, Valentine LE, Davis CW, Samuel MA, Hanna SL, Puffer BA, Doms RW, Virology 2005 334 28 40 10.1016/j.virol.2005.01.021 15749120 (Pubitemid 40320732)
16. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW, Virology 2006 346 53 65 10.1016/j.virol.2005.10.030 16325883 (Pubitemid 43254699)
17. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W, Am J Trop Med Hyg 2008 79 115 122 18606774 (Pubitemid 351957214)
18. Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. Vorndam V, Beltran M, Am J Trop Med Hyg 2002 66 208 212 12135295 (Pubitemid 34755655)
19. Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein. Liu L, Wen K, Li J, Hu D, Huang Y, Qiu L, Cai J, Che X, Clin Vaccine Immunol 2012 19 73 78 10.1128/CVI.05388-11 22116689
20. Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. Mattia K, Puffer BA, Williams KL, Gonzalez R, Murray M, Sluzas E, Pagano D, Ajith S, Bower M, Berdougo E, Harris E, Doranz BJ, PLoS One 2011 6 27252 10.1371/journal.pone.0027252 22096543
21. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. Burke CW, Mason JN, Surman SL, Jones BG, Dalloneau E, Hurwitz JL, Russell CJ, PLoS Pathog 2011 7 1002134 10.1371/journal.ppat.1002134 21750677
22. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R, J Virol 2006 80 5308 5320 10.1128/JVI.02460-05 16699011
23. A novel HIV-1 reporter virus with a membrane-bound Gaussia princeps luciferase. Suree N, Koizumi N, Sahakyan A, Shimizu S, An DS, J Virol Methods 2012 183 49 56 10.1016/j.jviromet.2012.03.028 22483780
24. Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination. van den Worm SH, Eriksson KK, Zevenhoven JC, Weber F, Zust R, Kuri T, Dijkman R, Chang G, Siddell SG, Snijder EJ, Thiel V, Davidson AD, PLoS One 2012 7 32857 10.1371/journal.pone.0032857 22412934
25. Biomineralization-based virus shell-engineering: towards neutralization escape and tropism expansion. Wang X, Deng Y, Li S, Wang G, Qin E, Xu X, Tang R, Qin C, Adv Healthc Mater 2012 1 443 449 10.1002/adhm.201200034 23184775
26. Dengue virus capsid protein usurps lipid droplets for viral particle formation. Samsa MM, Mondotte JA, Iglesias NG, Assuncao-Miranda I, Barbosa-Lima G, Da Poian AT, Bozza PT, Gamarnik AV, PLoS Pathog 2009 5 1000632 10.1371/journal.ppat.1000632 19851456
27. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. Konishi E, Tabuchi Y, Yamanaka A, J Virol Methods 2010 163 360 367 10.1016/j.jviromet.2009.10.026 19883692
28. Human skin Langerhans cells are targets of dengue virus infection. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS, Nat Med 2000 6 816 820 10.1038/77553 10888933 (Pubitemid 30469433)
29. A real-time PCR procedure for detection of dengue virus serotypes 1, 2, and 3, and their quantitation in clinical and laboratory samples. Conceicao TM, Da Poian AT, Sorgine MH, J Virol Methods 2010 163 1 9 10.1016/j.jviromet.2009. 10.001 19822173
30. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. Halstead SB, O'Rourke EJ, Allison AC, J Exp Med 1977 146 218 229 10.1084/jem.146.1.218 195000 (Pubitemid 8139504)
31. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. Yamanaka A, Kosugi S, Konishi E, J Virol 2008 82 927 937 10.1128/JVI.00992-07 18003724
32. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, Schlesinger JJ, Jin X, J Med Virol 2008 80 134 146 10.1002/jmv.21051 18041019 (Pubitemid 350220099)
33. Flow cytometry-based assay for titrating dengue virus. Lambeth CR, White LJ, Johnston RE, de Silva AM, J Clin Microbiol 2005 43 3267 3272 10.1128/JCM.43.7.3267-3272.2005 16000446 (Pubitemid 40981334)
34. Enzyme-linked immunosorbent assay-format tissue culture infectious dose-50 test for titrating dengue virus. Li J, Hu DM, Ding XX, Chen Y, Pan YX, Qiu LW, Che XY, PLoS One 2011 6 22553 10.1371/journal.pone.0022553 21799894
35. Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I, J Virol Methods 2010 163 205 209 10.1016/j.jviromet. 2009.09.018 19781573
36. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, Porter K, Rudiman IF, Yuwono D, Puthavathana P, Marovich MA, J Virol 2008 82 3939 3951 10.1128/JVI.02484-07 18272578 (Pubitemid 351521231)